Brussels, 07/01/2010 (Agence Europe) - On Thursday 7 January, the European Commission opened formal antitrust investigations into the practices of Danish pharmaceutical company Lundbeck suspected of breaking European competition rules through agreements that could hinder access to the European market of generic medicines to replace Citalopram, which it developed and marketed. Citalopram is an anti-depressant drug known to be a selective serotonin reuptake inhibitor. In July of last year, the...